1541 — ImmuneOnco Biopharmaceuticals Shanghai Balance Sheet
0.000.00%
Last trade - 00:00- HK$1.81bn
- HK$903.35m
- CNY154.29m
Annual balance sheet for ImmuneOnco Biopharmaceuticals Shanghai, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 668 | 635 | 609 | 752 | 1,016 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.034 | 0.991 | 0.948 | 0.016 | 0.001 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 704 | 652 | 687 | 868 | 1,057 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 164 | 174 | 159 | 47.7 | 33.5 |
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 893 | 840 | 875 | 922 | 1,098 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2,478 | 51.7 | 116 | 215 | 276 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Liabilities | 2,491 | 60.8 | 126 | 243 | 307 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -1,598 | 779 | 748 | 679 | 791 |
| Total Liabilities & Shareholders' Equity | 893 | 840 | 875 | 922 | 1,098 |
| Total Common Shares Outstanding |